Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance

Identification of Pyrrolo[2,3-d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia

(2019) Xue Yuan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia

(2019) Taylor M. Weis et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth in Vitro and in Vivo

(2018) Mark C. Weir et al.   ACS Chemical Biology

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Functional genomic landscape of acute myeloid leukaemia

(2018) Jeffrey W. Tyner et al.   NATURE

The Src family kinase Fgr is a transforming oncoprotein that functions independently of SH3-SH2 domain regulation

(2018) Kexin Shen et al.   Science Signaling

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

(2017) Richard M. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth

(2017) Mark C. Weir et al.   PLoS One

Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397

(2015) C. C. Smith et al.   Cancer Discovery

Trimmomatic: a flexible trimmer for Illumina sequence data

(2014) Anthony M. Bolger et al.   BIOINFORMATICS

SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia

(2014) Alexandre Puissant et al.   CANCER CELL

Activating FLT3 Mutants Show Distinct Gain-of-Function Phenotypes In Vitro and a Characteristic Signaling Pathway Profile Associated with Prognosis in Acute Myeloid Leukemia

(2014) Hanna Janke et al.   PLoS One

FLT3 Inhibitors in AML: Are We There Yet?

(2014) Akshay Sudhindra et al.   Current Hematologic Malignancy Reports

Kinase crystal identification and ATP-competitive inhibitor screening using the fluorescent ligand SKF86002

(2014) Lorien J. Parker et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents

(2013) C. Dos Santos et al.   BLOOD

A Pyrrolo-Pyrimidine Derivative Targets Human Primary AML Stem Cells in Vivo

(2013) Y. Saito et al.   Science Translational Medicine

A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3

(2012) Marshall A. Lichtman   BLOOD CELLS MOLECULES AND DISEASES

Small-Molecule Inhibitors of the c-Fes Protein-Tyrosine Kinase

(2012) Sabine Hellwig et al.   CHEMISTRY & BIOLOGY

A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff

(2012) Pablo Cingolani et al.   FLY

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

(2012) Catherine C. Smith et al.   NATURE

CHASM and SNVBox: toolkit for detecting biologically important single nucleotide mutations in cancer

(2011) Wing Chung Wong et al.   BIOINFORMATICS

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

(2010) A. McKenna et al.   GENOME RESEARCH

Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells

(2010) Y. Saito et al.   Science Translational Medicine

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro

(2009) N. von Bubnoff et al.   CANCER RESEARCH

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259

(2008) T Pene-Dumitrescu et al.   ONCOGENE